Financials data is unavailable for this security.
View more
Year on year Revolution Medicines Inc 's revenues fell -67.27% from 35.38m to 11.58m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 248.71m to a larger loss of 436.37m.
Gross margin | -- |
---|---|
Net profit margin | -76,423.31% |
Operating margin | -88,409.30% |
Return on assets | -41.28% |
---|---|
Return on equity | -47.18% |
Return on investment | -44.46% |
More ▼
Cash flow in USDView more
In 2023, Revolution Medicines Inc increased its cash reserves by 328.55%, or 536.03m. Cash Flow from Financing totalled 1.23bn or 10,614.85% of revenues. In addition the company used 350.57m for operations while cash used for investing totalled 342.60m.
Cash flow per share | -3.51 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.34 |
---|---|
Tangible book value per share | 8.91 |
More ▼
Balance sheet in USDView more
Current ratio | 14.24 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼